Results 31 to 40 of about 4,766 (189)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports

Drugs in Context, 2023
Background: Metabolic effects of integrase strand transfer inhibitors (INSTIs) have been reported. The FDA Adverse Event Reporting System (FAERS) is a publicly available database that captures spontaneously reported adverse events.
Milena M Murray, Lara Fakhouri, Spencer E Harpe   +2 more
doaj   +1 more source

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Retrovirology, 2009
Correction to Erik Serrao, Srinivas Odde, Kavya Ramkumar and Nouri Neamati: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:25.
Neamati Nouri, Ramkumar Kavya, Odde Srinivas, Serrao Erik   +3 more
doaj   +3 more sources

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis

Frontiers in Microbiology, 2020
The novel coronavirus SARS-CoV-2 disease “COVID-19” emerged in China and rapidly spread to other countries; due to its rapid worldwide spread, the WHO has declared this as a global emergency. As there is no specific treatment prescribed to treat COVID-19,
Rajaiah Alexpandi, Joelma Freire De Mesquita, Shunmugiah Karutha Pandian, Arumugam Veera Ravi   +3 more
doaj   +1 more source

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

mBio, 2017
Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis   +7 more
doaj   +1 more source

Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse   +5 more
wiley   +1 more source

Metods for acetamide determination in elvitegravir

, 2022
Elvitegravir je inhibitor HIV-1 integraze koji se u kombinaciji s drugim lijekovima koristi za liječenje infekcije virusom humane imunodeficijencije (HIV).
Grgić, Franciska
core  

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, Volume 32, Issue 3, Page 584-592, May/June 2026.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source

Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.

, 2016
Co-formulated elvitegravir, cobicistat, tenofovir disoproxil fumarate and emtricitabine is among the preferred regimens for first-line ART. A population approach was used to characterize the pharmacokinetics of elvitegravir and cobicistat and identify ...
Csajka, C., Rotger, M., Decosterd, L.A., Aouri, M., Buclin, T., Barceló, C., Guidi, M., Gaspar, F., Panchaud, A., Cavassini, M.   +9 more
core   +1 more source

PLGA-Encapsulated Elvitegravir and Curcumin Modulates ART Penetration, Oxidative Stress, and Inflammation

Brain Sciences
Background/Objectives: HIV persists in central nervous system (CNS) reservoirs, where infected microglia and macrophages drive neuroinflammation, oxidative stress, and neuronal damage, contributing to HIV-associated neurocognitive disorder (HAND ...
Sandip Godse, Lina Zhou, Namita Sinha, Golnoush Mirzahosseini, Santosh Kumar   +4 more
doaj   +1 more source

Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.

PLoS ONE, 2013
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in
Felix DeAnda, Kendra E Hightower, Robert T Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark R Underwood   +6 more
doaj   +1 more source